Hyderabad (Telangana) [India], September 25:In a landmark initiative to expand affordable breast cancer treatment in India, Hetero Healthcare Limited has announced the launch of Perzea, its most cost-effective biosimilar of Pertuzumab. Developed through a semi-exclusive collaboration with Enzene Biosciences Limited, this breakthrough aims to reduce the economic barriers faced by thousands of HER2-positive breast cancer patients.
Bringing Advanced Cancer Care Within ReachPertuzumab, a monoclonal antibody, is globally recognised as a HER2-positive breast cancer therapy when administered with trastuzumab and chemotherapy. Despite its proven efficacy, the high cost of treatment has restricted access in India. With Perzea, Hetero Healthcare is determined to change this reality, offering patients a therapy that balances global standards of care with local affordability.
Mr. M. Srinivas Reddy, Managing Director of Hetero Healthcare Limited, commented:“Our focus has always been to make advanced therapies more accessible without compromising on quality. With Perzea, we take a decisive step towards ensuring that no patient is denied life-saving care due to affordability challenges.”
Commitment to Patient-Centred HealthcareAligned with the Government of India's mission of equitable healthcare, Perzea strengthens Hetero Healthcare's legacy of delivering low-cost oncology medicines across critical therapeutic areas. For breast cancer patients and their families, this launch provides renewed hope by combining affordability with innovation.
About Hetero HealthcareHetero Healthcare Limited is among India's leading pharmaceutical companies, delivering high-quality medicines across oncology, antiretrovirals, and critical care. The company's focus on patient-centric innovation continues to drive better outcomes across India. Learn more: www.heterohealthcare.com
About Enzene BiosciencesEnzene is a fully integrated biologics innovator with its patented EnzeneX
Disclaimer: This article is for general information purposes only and should not be construed as professional medical advice. Always consult your doctor before taking any step.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor